Retrospective Case Series Analysis of Clinical Outcomes Associated with Management of Severe Community Acquired Pneumonia Cases due to K. pneumoniae with CSE-1034

Abstract

Background: In India, the rapid emergence of multi-drug resistance among community acquired pneumonia (CAP) causing pathogens contributes to the seriousness of these infections and is currently a major treatment-related issue. The objective of this case series was to determine the clinical efficacy of antibiotic adjuvant entity (CSE-1034: Ceftriaxone+Sulbactam+EDTA) in severe CAP cases. Methods: Severe CAP patients due to K. pneumoniae who were hospitalized and treated with CSE-1034 as monotherapy or combination therapy were screened and further analyzed. CSE-1034 therapy was started in all these subjects based on culture sensitivity (C/s) profile and continued or discontinued depending on clinical response.  Results: 25 K. pneumoniae culture-positive patients with mean age of 52 years were included in this case series. C/s profile has shown that pathogens isolated from all subjects were completely resistant to amikacin, cefazolin, ceftriaxone, pipericillin-tazobactam (pip-taz) and cefoperazone/sulbactam. Sensitivity pattern of CSE-1034 was 100% and meropenem was 85%. The C/s reports and clinical response to CSE-1034 were in concordance in 92% patients. 23/25 (92%) patients treated with CSE-1034 were cured with CSE-1034 monotherapy and 2/25 (8%) with CSE-1034+colistin combination therapy. Conclusion: From this case series, it can be presumed that CSE-1034 can serve as effective replacement to BL/BLI combinations and appears to be effective drug for treatment of severe CAP cases.